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Abstract: BACKGROUND Early discharge of patients with acute low-risk pulmonary embolism (PE)
requires validation by prospective trials with clinical and quality of life outcomes. METHODS The
multinational Home Treatment of Pulmonary Embolism (HoT-PE) single-arm management trial inves-
tigated early discharge followed by ambulatory treatment with rivaroxaban. The study was stopped for
efficacy after the positive results of the predefined interim analysis at 50% of the planned population.
The present analysis includes the entire trial population (576 patients). In addition to three-month
recurrence (primary outcome) and one-year overall mortality, we analysed self-reported disease-specific
(Pulmonary Embolism Quality of Life [PEmb-QoL] questionnaire) and generic (five-level five-dimension
EuroQoL [EQ-5D-5L] scale) quality of life as well as treatment satisfaction (Anti-Clot Treatment Scale
[ACTS]) after PE. RESULTS The primary efficacy outcome occurred in three (0.5%; upper 95.0% CI
1.3%) patients. One-year mortality was 2.4%. The mean PEmb-QoL decreased from 28.9±20.6% at 3
weeks to 19.9±15.4% at 3 months, a mean change (improvement) of -9.1% (p<0.0001). Improvement
was consistent across all PEmb-QoL dimensions. EQ-5D-5L was 0.89±0.12 3 weeks after enrolment and
improved to 0.91±0.12 at 3 months (p<0.0001). Female sex and cardiopulmonary disease were associated
with poorer disease-specific and generic quality of life; older age, with faster worsening of generic quality
of life. The ACTS burden score improved from 40.5±6.6 points at 3 weeks to 42.5±5.9 at 3 months
(p<0.0001). CONCLUSIONS Our results further support early discharge and ambulatory oral anticoag-
ulation for selected patients with low-risk PE. Targeted strategies may be necessary to further improve
quality of life in specific patient subgroups.
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Background. Early discharge of patients with acute low-risk pulmonary embolism (PE) 
requires validation by prospective trials with clinical and quality of life outcomes. 
Methods. The multinational Home Treatment of Pulmonary Embolism (HoT-PE) single-arm 
management trial investigated early discharge followed by ambulatory treatment with 
rivaroxaban. The study was stopped for efficacy after the positive results of the predefined 
interim analysis at 50% of the planned population. The present analysis includes the entire 
trial population (576 patients). In addition to three-month recurrence (primary outcome) and 
one-year overall mortality, we analysed self-reported disease-specific (Pulmonary Embolism 
Quality of Life [PEmb-QoL] questionnaire) and generic (five-level five-dimension EuroQoL 
[EQ-5D-5L] scale) quality of life as well as treatment satisfaction (Anti-Clot Treatment Scale 
[ACTS]) after PE. 
Results. The primary efficacy outcome occurred in three (0.5%; upper 95.0% CI 1.3%) 
patients. One-year mortality was 2.4%. The mean PEmb-QoL decreased from 28.9±20.6% at 
three weeks to 19.9±15.4% at three months, a mean change (improvement) of -9.1% (p 
<0.0001). Improvement was consistent across all PEmb-QoL dimensions. EQ-5D-5L was 
0.89±0.12 three weeks after enrolment and improved to 0.91±0.12 at three months 
(p<0.0001). Female sex and cardiopulmonary disease were associated with poorer disease-
specific and generic quality of life; older age, with faster worsening of generic quality of life. 
The ACTS burden score improved from 40.5±6.6 points at three weeks to 42.5±5.9 at three 
months (p<0.0001).
Conclusions. Our results further support early discharge and ambulatory oral anticoagulation 
for selected patients with low-risk PE. Targeted strategies may be necessary to further 
improve quality of life in specific patient subgroups. 































































The severity spectrum of acute pulmonary embolism (PE) is broad, ranging from 
asymptomatic, incidentally diagnosed events to cases in which PE compromises the patient’s 
haemodynamic status and represents an immediately life-threatening condition. Initial risk 
assessment is mandatory for optimising initial treatment and deciding on the most appropriate 
setting in which this treatment will be delivered. As proposed by the recent 2019 European 
Society of Cardiology (ESC) Guidelines for the diagnosis and management of acute 
pulmonary embolism, developed in collaboration with the European Respiratory Society 
(ERS), such a risk-adjusted management strategy consists of a stepwise approach combining 
clinical findings, imaging, and biochemical markers [1]. Criteria for identifying the group of 
patients whose risk is ‘sufficiently low’ to permit early discharge and ambulatory treatment 
have been tested in prospective management studies, and include the absence of severe 
comorbidities, the absence of signs of right ventricular dysfunction, and an adequate social 
and familiar support [2-7]. Despite these efforts, registry data indicate that only 10% of 
patients admitted to large European centres with acute pulmonary embolism are discharged 
‘immediately’, and more than half of the patients spend 5 days or more in hospital [8]. Early 
discharge and home treatment may minimise hospitalization-related complications [9], reduce 
healthcare costs [10, 11], and improve the quality of life of affected patients [12]. 
Over the past decade, non-vitamin-K-dependent oral anticoagulants (NOACs) became 
the standard of care for the treatment of acute pulmonary embolism [1]. The fact that their use 
requires no periodic blood testing explains, at least in part, the higher patient-reported 
treatment satisfaction [13, 14]. Furthermore, early transition from hospital to ambulatory care 
may be facilitated, since at least some of the NOACs do not require an initial lead-in 
treatment with parenteral low-molecular-weight heparin and thus offer an appealing 
perspective both for (selected) patients and for caregivers. 






























































In 2019, the results of the predefined interim analysis of the multinational Home 
Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor 
Rivaroxaban (HoT-PE) trial were published. Initiation of anticoagulation with rivaroxaban 
followed by early discharge and continuation of treatment at home was shown to be effective 
and safe in patients with acute low-risk pulmonary embolism based on a combination of 
clinical criteria and the absence of right ventricular (RV) dysfunction on imaging [5]. These 
findings permitted premature termination of the study after completion of three-month follow-
up of the first 525 patients. The present study provides the results of the complete analysis of 
the HoT-PE study, including the patients enrolled while the interim analysis was being 
performed and focusing on the evaluation of key long-term outcomes, such as the quality of 
life and treatment satisfaction, along with 12-month mortality. 
Methods
Study Design and Participants 
HoT-PE (EudraCT Nr. 2013-001657-28) is a prospective multicentre single-arm investigator-
initiated phase 4 interventional trial sponsored by the University Medical Centre Mainz, 
Germany [15]. The institutional ethics review board of each participating site approved the 
study and patients provided written informed consent for participation. A description of the 
study rationale and background for the eligibility criteria has been explained previously [15]. 
Briefly, adult patients were eligible for inclusion if they had objectively confirmed acute 
pulmonary embolism without RV enlargement or dysfunction (right/left ventricular [RV/LV] 
diastolic diameter ratio ≥ 1.0) and no free-floating thrombi in the right atrium or ventricle by 
echocardiography or computed tomographic pulmonary angiography (CTPA). Patients were 
also excluded if they had haemodynamic instability at presentation; active bleeding or known 
significant bleeding risk; need for supplemental oxygen administration; chronic treatment 
with anticoagulant drugs; pain requiring parenteral administration of analgesic agents; other 






























































medical conditions requiring hospitalization; non-compliance or inability to adhere to the 
treatment or the follow-up visits, or lack of a family environment or support system; and 
contraindications to rivaroxaban therapy. 
Treatment
Initiation of treatment with an approved parenteral or oral anticoagulant (unfractionated 
heparin, low-molecular-weight heparin, fondaparinux, rivaroxaban, or apixaban) no later than 
three hours after pulmonary embolism diagnosis was allowed before enrolment in the study. 
Patients received the first dose of the study medication, rivaroxaban, within two hours of the 
next due dose of subcutaneous injection of low-molecular-weight heparin or fondaparinux (or 
oral rivaroxaban or apixaban), or at the time of discontinuation of intravenous unfractionated 
heparin. The rivaroxaban regimen corresponded to the label of the marketed product, 
consisting of 15 mg twice daily for three weeks followed by the maintenance regimen of 20 
mg once daily for at least three months. Reduction of the maintenance dose to 15 mg once 
daily was allowed in patients estimated to have a high risk of bleeding including those with a 
creatinine clearance below 50 ml/min. The trial protocol mandated discharge within 48 hours 
of admission, or a maximum of two nights in hospital [15]. 
Study Outcomes 
The primary efficacy outcome was symptomatic recurrent venous thromboembolism, or 
pulmonary embolism-related death within three months of enrolment. The secondary efficacy 
outcomes included all-cause death within three months and one year of enrolment, 
rehospitalisations due to PE or to a bleeding event within three months as well as the 
assessment of validated quality of life and treatment satisfaction questionnaires. The safety 
outcomes included major bleeding (defined by the criteria of the International Society on 
Thrombosis and Haemostasis) [16], clinically relevant non-major bleeding, and serious 






























































adverse events. All efficacy and safety outcomes were adjudicated by an independent clinical 
events committee. 
Quality of Life and Treatment Satisfaction Questionnaires
We analysed the data on the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire 
for the assessment of disease-specific quality of life [17]; the five-level five-dimension 
EuroQoL (EQ-5D-5L) scale for generic quality of life measured 3 weeks and 3 months after 
enrolment [18]; and the Anti-Clot Treatment Scale (ACTS), a patient-reported measure of 
anticoagulant treatment satisfaction [13]. In brief, PEmb-QoL is composed of 40 items and 
serves to quantify health-related quality of life across six health dimensions: (1) frequency of 
complaints, (2) activities of daily living limitations, (3) work-related problems, (4) social 
limitations, (5) intensity of complaints, and (6) emotional complaints. Two questions of the 
questionnaire focus on the time of the day at which the symptoms appear, and the state of the 
patient’s current condition compared with one year before, and do not contribute to the total 
score. The six dimensions contributing to scores are summed, weighted, and transformed to a 
percentage scale (0 to 100), with higher scores indicating worse quality of life and lower 
scores indicating better quality of life. 
EQ-5D-5L (© EuroQol Research Foundation; EQ-5DTM is a trade marke of the 
EuroQol Research Foundation) is a validated instrument designed to provide a simple and 
direct profile of the patient’s generic health status (https://euroqol.org/publications/user-
guides). It comprises a short descriptive system questionnaire covering five dimensions 
(mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual 
analogue scale ranging from 0 (“the worst health the patient can imagine”) to 100 (“the best 
health the patient can imagine”). Each of the five dimensions is composed of five levels of 
severity. EQ-5D-5L can also be analysed after conversion and weighting of the results of 
these dimensions into a single summary index value. Calculation of EQ-5D-5L index score 






























































was based on the coding available at https://euroqol.org/eq-5d-instruments/eq-5d-5l-
about/valuation-standard-value-sets/crosswalk-index-value-calculator/.
Finally, the ACTS (ACTS © Bayer AG, 2006. All Rights Reserved.) includes 12 items 
assessing perceived burden, and 3 items assessing perceived benefits from treatment. Each 
item can be rated from the lowest intensity 1 (not at all) to the highest intensity 5 (extremely) 
with totals comprised between 12-60 (burdens) and 3-15 (benefits). After reversing of the 
scale, higher ACTS scores indicate greater treatment satisfaction.
Sample Size Calculation 
The null hypothesis (H0) that p ≥ 0.03 (p being the probability of recurrent VTE or PE-related 
death within 3 months) was tested against the alternative hypothesis (H1) that p < 0.03, using 
a binomial test (2-stage adaptive design based on an O’Brien Fleming design) and assuming a 
3-month symptomatic VTE recurrence rate of 1.7%, similar to that reported in a meta-analysis 
of studies dating back to the vitamin K antagonist era [19] and to the three-month recurrence 
rate observed in the EINSTEIN-PE rivaroxaban phase 3 trial [20]. The study was stopped 
after the preplanned interim analysis performed after enrolment and 3-month evaluation of the 
first 525 patients, as H0 could be rejected at the local level of α = 0.004 (<6 patients 
developing the primary efficacy outcome) in the intention-to-treat (ITT) population [5]. 
Statistical Analysis
The primary and secondary outcome analysis was done in the ITT population, consisting of 
patients who signed the informed consent. Safety analysis was conducted in the safety 
population, including all patients who received at least one dose of study drug. Per-protocol 
analysis was carried out as a sensitivity analysis for the primary outcome, including all 
patients who received at least one dose of study drug and fulfilled the protocol requirements 
for early discharge from the hospital. 






























































Differences of the quality of life scores between 3-week and 3-month visits were done 
using paired t-tests in case of normally distributed data or using the Wilcox-signed-rank test. 
To check for associations between baseline pre-defined explanatory variables characterized 
by low multicollinearity and an outcome variable (PEmb-QoL, Visual Analogue Scale), a 
linear regression model was fitted for the 3-week and 3-month visit as well as for the 
difference between 3 weeks and 3 months. For each linear regression model, the assumption 
of normal distributed residuals was confirmed. In case the number of missing values for both 
explanatory and outcome variable(s) was low (< 5%), an imputation technique was not 
deemed to be crucial. 
Results
From May 2014 through June 2018, a total of 576 patients signed the informed consent for 
participation in the HoT-PE trial at 49 centres in 7 countries and were included in the ITT 
population. The mean age was 57 (range 18-90) years and 266 (46.2%) were women. Table 1 
displays the baseline characteristics of the study population. Dyspnoea (61.3%), pleuritic pain 
(40.6%), cough (10.7%), and retrosternal pain (20.7%) represented the most frequent 
symptoms of pulmonary embolism, followed by fever (7.5%), haemoptysis (4.9%), and 
syncope (3.0%). Unilateral leg pain and unilateral oedema were present in 24.8% and 15.6% 
of patients, respectively. The onset of symptoms preceeded the diagnosis of acute pulmonary 
embolism by a median of 4 (Q1-Q3: 2-8) days. CTPA was the most frequently used imaging 
test for diagnosis (n=528, 91.7%). Deep vein thrombosis was present in 241 (53.2%) of 453 
patients in whom compression ultrasound was performed.
A total of of 569 (98.8%) patients who received at least one dose of rivaroxaban were 
included in the safety population. The median length of hospitalisation was 33 (Q1-Q3: 23-
47) hours, and 551 patients were hospitalised for up to two nights in compliance with the 
study protocol. A total of 547 (95.0%) patients were included in the per-protocol population.






























































Rivaroxaban 15 mg twice daily was given for a mean period of 21 (standard deviation 
[SD] 5) days after the diagnosis of acute pulmonary embolism. Patients received the 
maintenance dosage of rivaroxaban over an additional period of 69 (SD 10) days. 




The primary efficacy outcome, symptomatic recurrent venous thromboembolism or 
pulmonary embolism-related death occurred in three (0.5%; one-sided upper 95.0% 
confidence interval [CI] 1.3%; one-sided p-value <0.0001) of the 576 patients of the ITT 
population within three months of enrolment; Table 2. All three recurrent events were 
nonfatal recurrent PE (Supplementary Material I, Table S1). The primary outcome occurred in 
two (0.4%; two-sided 95% CI 0.04-1.3%; two-sided p-value <0.0001) of the 547 patients 
included in the per-protocol population.
Safety and Secondary Efficacy Outcomes
Of the 569 patients included in the safety population, six (1.1%, two-sided 95% CI 0.4-2.3%) 
had a major bleeding episode during rivaroxaban treatment within 3 months of enrolment. 
Clinically relevant non-major bleeding was recorded in 30 (5.3%; two-sided 95% CI 3.6-
7.4%) patients. The median duration of first rehospitalisation was 6 (Q1-Q3: 3-9) days. 
Serious adverse events within 3 months of enrolment occurred in 68 (12.0%) patients, of 
which 64 required rehospitalisation. An overview of these events is provided in Table S2. 
Twelve (2.1%) patients were hospitalised for suspected pulmonary embolism recurrence or 
bleeding within 3 months of enrolment, which was then confirmed in 7 (1.2%).  
Fourteen patients died after a median of 6.8 (Q1-Q3 4.7-11.4) months, corresponding 
to a one-year mortality rate of 2.4% (95% CI 1.3-4.0%). Cancer was the most frequent cause 






























































of death and was recorded in nine patients. The three-month mortality rate was 0.4% (95% CI 
0.04-1.25%), and both deaths were due to progressive metastatic cancer. 
Analysis of Quality of Life Questionnaires
Analysis of the PEmb-QoL was conducted on a total of 425 patients who completed the 
questionnaire at both visits. The formulas for the calculation of the PEmb-QoL questionnaire 
are shown in Supplementary Material II. The mean PEmb-QoL score decreased from 28.9% 
(SD 20.6%) at 3 weeks to 19.9% (SD 18.4%) at 3 months; this corresponds to a mean 
reduction of -9.1% (SD 15.4%; paired t-test <0.0001), indicating a significant improvement in 
the patients’ self-reported quality of life. As displayed in Figure 1, the improvement was 
consistent across all PEmb-QoL dimensions. In our multivariable linear regression model 
(Table 3), female sex, higher body-mass index, and the presence of cardiopulmonary disease 
were associated with a poorer quality of life (indicated by a higher PEmb-QoL score) at both 
week 3 and month 3 of the follow-up. Of note, older age and the presence of cancer were not 
associated with worse quality of life at these timepoints, but they were associated with ‘faster 
worsening’ of disease-specific quality of life over time. Specifically, we documented a +0.2% 
relative increase in the slope (per unit increase) between week 3 and month 3 per year of age 
(p=0.001), and a +6.4% relative increase in patients with (versus without) cancer (p=0.001). 
In Tables S3 and S4 (Supplementary Material I), we separately show the results of the 
two PEmb-QoL dimensions not included in the calculation of the score, which serve to 
qualitatively assess the time of the day when the patient’s symptoms were perceived as being 
more intense (Dimension 2) and whether symptoms are more severe compared with one year 
before (Dimension 3). The characteristics of the patients with and without complete PEmb-
QoL assessment at both visits are reported in Table S5.
The EQ-5D-5L analysis was conducted in a total of 473 patients who filled the 
questionnaire at both visits. The EQ-5D-5L index score was 0.89 (SD 0.12) 3 weeks after 






























































enrolment and improved to 0.91 (SD 0.12) at 3 months (paired t-test for difference; 
p<0.0001). The number of patients reporting ‘no problems’ in any of the five dimensions 
increased from 61.2% at week 3 to 72.0% at month 3, paralleled by a consistent reduction of 
the proportion of patients with slight (from 25.7% to 18.4%), moderate (from 10.3% to 7.4%), 
severe (from 1.9% to 1.8%), or extreme (from 0.3% to 0.2%) problems. As displayed in 
Figure 2, these positive changes were consistent across all five EQ-5D-5L dimensions. 
The Visual Analogue Scale of the EQ-5D-5L increased from 76.2 (SD 16.1) to 80.2 
(SD 16.4) points (paired t-test for difference; p<0.0001). In our multivariable linear regression 
model (Table 3), female sex and the presence of cardiopulmonary disease were associated 
with a lower Visual Analogue Scale, indicating a poorer quality of life, at both week 3 and 
month 3. Older age was associated with faster worsening of generic quality of life according 
to the Visual Analogue Scale (-0.1% relative decrease per year of age between week 3 and 
month 3; p=0.02). The characteristics of the patients with and without complete EQ-5D-5L 
assessment are reported in Table S6.
Anti-Clot Treatment Scale (ACTS)
The analysis was conducted on a total of 421 patients who completed the questionnaire at 
both visits. After 3 weeks, the percentage of patients not reporting none of the ACTS burden 
items was 56.9%, and increased to 66.0% after 3 months. The ACTS burden score increased 
from 40.5 (SD 6.6) at week 3 to 42.5 (SD 5.9) points at month 3, indicating an improvement 
in terms treatment satisfaction (paired t-test; p<0.0001). Three weeks after acute PE, 26.3% of 
the patients reported to be ‘extremely satisfied’ based on the ACTS benefit items; this 
percentage increased to 31.7% at 3 months. The ACTS benefit score was 11.4 (SD 2.9) at 
week 3, and 11.4 (SD 3.1) at month 3 (paired t-test; p=0.4189). 
Discussion






























































This report presents a comprehensive analysis of clinical outcomes and self-reported quality 
of life in the entire population of the HoT-PE study, a prospective multinational investigator-
initiated and academically sponsored phase 4 trial. The results of the predefined interim 
analysis yielded low rates of the primary outcome, symptomatic or fatal recurrence of venous 
thromboembolism at three-month follow-up [5], and thus allowed for early termination of the 
trial. The present analysis focuses on long-term survival as well as the quality of life and its 
change over time following early discharge of patients with acute low-risk pulmonary 
embolism. Our results, obtained in 576 patients, confirm the low rate of the primary efficacy 
outcome and show low all-cause mortality at 12-month follow-up (2.4%). Moreover, and 
importantly, the HoT-PE study quantitatively assessed the course of the patients’ disease-
specific and generic quality of life, as measured by established standardised scores, over the 
first three months of oral anticoagulant treatment for pulmonary embolism. By identifying 
predictors of a poor or worsening score among the patients’ key baseline characteristics, our 
data may help to design future research on targeted strategies aiming to improve the quality of 
life of specific patient subgroups after acute pulmonary embolism. 
The rate of efficacy outcome in the entire population of our trial is in agreement with 
the low rates reported in phase 3 anticoagulation trials which enrolled patients with venous 
thromboembolism [21], and in pragmatic management studies of patients with low-risk 
pulmonary embolism [22, 23]. This is also true for the rate of safety outcomes, notably major 
haemorrhage [21-23]. We recently reported that, within this low-risk population, ‘fragile’ 
patients defined by age above 75 years, a low body mass index (<18.5 kg/m2), or a creatinine 
clearance of less than 50 mL/min, exhibited a higher rate of major bleeding (2.7%, compared 
to 0.7% among patients with none of these characteristics) [24]. While these characteristics do 
not, by themselves, represent contraindications to early discharge and home treatment of acute 
low-risk pulmonary embolism, closer surveillance may be warranted for prevention or early 
detection of bleeding complications. 






























































The notion that our study successfully defined and enrolled a patient population with 
‘truly’ low-risk pulmonary embolism is supported by the very low 12-month (2.4%) overall 
mortality rates; in fact, out of 14 total deaths recorded over the entire one-year follow-up 
period, nine were due to active cancer as the underlying disease of the patient’s index episode 
of pulmonary embolism. These numbers are in sharp contrast to the rates previously reported 
in the literature; in those earlier reports, one-year mortality rate overall exceeded 15% among 
unselected patients with pulmonary embolism [25, 26] or venous thromboembolism in the 
broader sense [27-29], ranging between 40% among patients with cancer and 10% among 
those without it.
Beyond delivering data on recurrence, bleeding and overall mortality, HoT-PE is the 
largest study that has prospectively evaluated, using established standardised questionnaires, 
the patients’ quality of life three weeks and three months after acute (low-risk) pulmonary 
embolism. Both the disease-specific and the generic tools measuring the quality of life 
indicated a significant improvement over time, although no definitive conclusion can be 
drawn that a causal association exists between early discharge followed by home oral 
rivaroxaban anticoagulation on quality of life parameters in the absence of a control group. 
Seen from a different perspective however, our results also show that pulmonary embolism 
continues to represent, over a considerable period of several weeks or months, a source of 
major discomfort, and it may interfere with several aspects of the patient’s work, daily 
activities and social life, even if the index episode fulfilled strict criteria of ‘low risk’. The 
degree of improvement over time was similar across different scales and dimensions of 
quality of life. Female sex, higher body-mass index, and a history of cardiac or pulmonary 
disease were associated with a poorer quality of life at a given time point in follow-up 
according to the validated disease-specific PEmb-QoL score; female sex and cardiac or 
pulmonary disease also correlated with a lower generic quality of life according with the 
Visual Analogue Scale (Table 3). Older age correlated with a faster worsening of both 






























































indexes over time. This analysis in a large low-risk population is generally in line with the 
results of prior studies reporting on follow-up after pulmonary embolism [30-32]. In fact, 
studies of patients suffering stroke or myocardial infarction have also pointed to a similar 
direction, particularly concerning age, sex and body-mass index [33-35], indicating that the 
impact of specific baseline characteristics on the quality of life over time is consistent across a 
broad spectrum of acute cardiovascular syndromes.
Our study has some limitations which need to be pointed out. Routine assessment of 
RV function has been proposed to possess added value for risk stratification of pulmonary 
embolism independently from clinical assessment tools [36], but the optimal imaging method, 
CTPA versus transthoracic echocardiography, remains unclear. Moreover, it is sometimes 
argued that the latter imaging modality may not be available on a continuous basis in all 
hospitals. In HoT-PE, CTPA was performed for diagnosis of initial acute PE in the vast 
majority (> 90%) of the study patients. It has been shown that a simple parameter of RV 
function on CTPA, the calculation of the RV/LV ratio, was accurate and reproducible after 
minimal training [37]. These facts argue against feasibility problems in following the strategy 
tested in HoT-PE. A further limitation of our study is that complete data for self-reported 
quality of life or treatment satisfaction were available, for both follow-up visits, in 
approximately 75% of the study patients. For absolute transparency, we have included, in the 
supplementary material, two tables showing the baseline characteristics of the patients with 
versus those without complete questionnaire data. Other potential limitations of our trial, 
including the ‘cautiousness’ of the eligibility criteria, have previously been addressed in detail 
[5]. On the other hand, the strengths of the prospective HoT-PE study lie in the rigorous 
monitoring, the independent adjudication of the efficacy and safety outcomes, the large size 
of the study for this particular patient population, and most of all in the fact that it can be 
considered a representative European management trial, having included 49 centres in seven 
countries with different population characteristics and healthcare systems.






























































In conclusion, the results of the complete analysis of the HoT-PE trial support the 
early discharge and ambulatory oral anticoagulation treatment of carefully selected patients 
with acute low-risk pulmonary embolism. Anticoagulation with rivaroxaban initiated in the 
hospital and continued over at least three months was effective and safe. All-cause mortality 
was extremely low over the entire 12-month follow-up period. The patients’ quality of life 
improved early during follow-up as assessed on the basis of standardised, disease-specific and 
generic quality of life questionnaires. Future early-discharge strategies may need to target 
individuals with specific baseline characteristics such as female sex, an increased body-mass 
index, and a history of cardiac or pulmonary disease. 
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FIGURE 1 Improvement of quality of life after acute pulmonary embolism according to the 
Pulmonary Embolism Quality of Life score
The figure illustrates the evolution in disease-specific quality of life for each of the PEmb-QoL 
dimensions and for the whole PEmb-QoL score between Week 3 (blue line) and Month 3 (orange line). 
The six dimensions contributing to scores are summed, weighted, and transformed to a percentage scale 
(0 to 100), with higher scores (larger area of the polygon) indicating worse quality of life and lower 
scores (smaller area of the polygon) indicating better quality of life.
PEmb-QoL: Pulmonary Embolism Quality of Life questionnaire.






























































FIGURE 2 Graphic representation of the course of EQ-5D-5L assessed 3 weeks and 3 
months after enrolment
Stacked bar plots showing the percentage of patients reporting “no problems”, “slight problems”, 
“moderate problems” or “severe problems” in each of the five dimensions of the EQ-5D-5L health-
related quality of life questionnaire and in the overall questionnaire at 3 weeks and 3 months.






























































TABLE 1 Baseline characteristics of the study population
Variable Value
Patient Demographics
Age (years), mean (SD; range) 56.5 (16.6; 18-90)
Women, n/N (%) 266/576 (46.2)
Caucasian 567/576 (98.4)
Education Level
Elementary school, n/N (%) 20/519 (3.9)
Basic primary school 58/519 (11.2)
Secondary general school 123/519 (23.7)
Intermediate secondary school 132/519 (25.4)
A-level 95/519 (18.3)
University degree 90/519 (17.3)
Doctorate 1/519 (0.2)
Functional Parameters and Biochemical Markers
Body mass index (kg/m²), median (Q1-Q3) 27.1 (24.3-30.5)
Systolic / diastolic blood pressure (mm Hg), mean (SD) 136 (19) / 80 (12)
Heart rate (beats per minute), mean (SD) 78 (13)
Oxygen saturation (%), median (Q1-Q3) 97 (96-98)
Respiratory rate (breaths per minute), median (Q1-Q3) 16 (15-18)
Creatinine clearance < 50 mL/min 32 (5.6)
Risk Factors for Pulmonary Embolism and Comorbidities, n/N (%)
Oestrogen use 92/571 (16.1)
Immobilisation (for at least 3 days) 58/570 (10.2)
Previous deep vein thrombosis 87/566 (15.4)
Previous pulmonary embolism 44/572 (7.7)
Recent major surgery (past 30 days) 38/574 (6.6)






























































Recent major trauma (past 30 days) 25/575 (4.3)
Long travel (> 4 hours, past 30 days) 70/567 (12.3)
Active cancer 38/567 (6.7)
Chronic obstructive pulmonary disease 28/569 (4.9)
Chronic heart failure 7/575 (1.2)
Coronary artery disease 41/570 (7.2)
Arterial hypertension 241/574 (42.0)
Diabetes mellitus 38/576 (6.6)
Simplified Pulmonary Embolism Severity Index (sPESI) ≥ 1 127/556 (22.8)
Baseline Imaging Tests for Venous Thromboembolism, n/N (%)
Computed tomography pulmonary angiogram 528/575 (91.8)
Lung ventilation/perfusion scan 48/574 (8.4)
Pulmonary angiogram 27/560 (4.8)
Compression ultrasound 453/573 (79.1)
Deep vein thrombosis confirmed 241/453 (41.8)
For categorical variables, the proportion and percentage of valid (non-missing) cases are reported. 
Continuous variables with missing information: body mass index (18 patients), blood pressure (19 
patients), oxygen saturation (20 patients), respiratory rate (70 patients).
Q1-Q3: first and third quartile; SD: standard deviation.






























































TABLE 2 Study outcomes
Primary Efficacy Outcome 
Primary outcome (intention-to-treat population): recurrent venous 
thromboembolism or fatal PE, n/N (%; one-sided upper 95.0% CI) 
3/576 (0.5; 1.3)
Recurrent PE, n 3
Recurrent deep vein thrombosis, n 0
Death related to PE, n 0
Primary outcome (per-protocol population): recurrent venous 
thromboembolism or fatal PE, n/N (%; two-sided 95% CI)
2/547 (0.4; 0.04-1.3)
Secondary Efficacy Outcomes
Death of any cause within 3 months, n/N (%) 2/576 (0.4)
Death of any cause within 12 months, n/N (%; two-sided 95% CI) 14/576 (2.4; 1.3-4.0)








Major bleedinga, n/N (%; 95% CI) 6/569 (1.1; 0.4-2.3) 
Clinically relevant bleeding, n/N (%; 95% CI) 30/569 (5.3; 3.6-7.4)
At least one serious adverse event, n/N (%; 95% CI) 68/569 (12.0; 9.5-14.9)
Serious adverse events requiring prolonged initial hospitalization, 
or rehospitalization, n/N (%; 95% CI)
64/576 (11.1; 8.8-13.9)
aAs defined by the criteria of the International Society of Thrombosis and Haemostasis [16]. 
CI: confidence interval; PE: pulmonary embolism.






























































TABLE 3 Association between baseline clinical characteristics and quality of life scores 3 weeks and 3 months after enrolment
PEmb-QoL (Week 3) PEmb-QoL (Month 3)
Visual Analogue Scale 
(Week 3)


































Age (per unit 
increase)









-3.9 1.7 0.02 -4.6 1.7 0.007
BMI (per unit 
increase) 
0.5 0.2 0.02 0.5 0.2 0.008 0.04 0.1 0.77 0.1 0.1 0.52





3.0 2.6 0.24 1.0 2.3 0.67 -3.3 1.9 0.08 -0.5 1.9 0.80
















































Prior VTE 0.1 2.6 0.97 -0.2 2.3 0.95 0.9 1.9 0.66 1.1 1.9 0.58
Cardiopulmon
ary disease 




Active cancer -1.1 4.1 0.79 5.4 3.6 0.14 -4.6 3,1 0.15  -7.2  3.1  0.02
Intercept 16.4 7.0 0.02 -1.4 6.2 0.82 82.7 5.1
<0.00
01
 90.9  5.1
 <0.00
01
The beta estimates for the difference of Pulmonary Embolism Quality of Life (PEmb-QoL) score between Week 3 and Month 3 were +0.2 (standard error 0.05; 
p=0.001) relative increase for age and +6.4 (standard error 3.1; p=0.04) relative increase for cancer, indicating a faster worsening of quality of life with 
progressively older age and in patients with (vs. without) cancer. The beta estimates for the difference of Visual Analogue Scale between Week 3 and Month 3 
were -0.1 (standard error 0.04; p=0.02), indicating a faster worsening of quality of life with progressively older age.
*Positive estimates of the PEmb-QoL questionnaire score indicate an association with a worse quality of life (vs. reference group, corresponding to the absence 
of the factor, or per unit increase) 3 weeks and 3 months after enrolment. **Positive estimates of the Visual Analogue Scale indicate an association with a better 
quality of life (vs. reference group, corresponding to the absence of the factor, or per unit increase) 3 weeks and 3 months after enrolment. 




























































































































Female, 46 0 Recurrent PE 20 mg once 
daily
29 4 Segmental recurrent PE 
occurring during rivaroxaban 
therapy. No haemodynamic 
decompensation.
Rivaroxaban 
discontinuation and switch 
to LMWH. No further 
complications.
Male, 46 ≥ 1 Recurrent PE 15 mg twice 
daily
7 6 Segmental recurrent PE 
occurring during rivaroxaban 
therapy. No haemodynamic 
decompensation.
The therapy with 
rivaroxaban (15 mg twice 
daily) was continued. No 
further complications.
Female, 47 0 Recurrent PE 20 mg once 
daily
75 - Segmental recurrent PE 
occurring during rivaroxaban 
therapy. No haemodynamic 
decompensation.
Rivaroxaban 
discontinuation and switch 
to LMWH; no further 
complications.
Female, 37 0 Major bleedinga 15 mg twice 
daily
12 1 Uterine bleeding. Rivaroxaban 
discontinuation and switch 
to LMWH.

















































Male, 81 ≥ 1 Major bleedinga 20 mg once 
daily
57 12 Haemorrhagic shock following 
acute bleeding from intestinal 
diverticula. 
Red blood cell 
concentrates; rivaroxaban 
discontinuation and switch 
to LMWH. Subsequently, 
the patient suffered one 
further gastrointestinal 
major bleeding episode on 
heparin.
Female, 69 0 Major bleedinga 20 mg once 
daily
70 - Gastrointestinal bleeding (onset 
10 days before) and anaemia.
-
Female, 50 0 Major bleedinga 15 mg once 
daily




Female, 49 0 Major bleedinga 20 mg once 
daily
57 6 Uterine bleeding (onset 20 days 
before).
Red blood cell 
concentrates; rivaroxaban 
discontinuation and switch 
to LMWH.
Male, 85 ≥ 1 Major bleedinga 20 mg once 
daily
72 69 Intracranial haemorrhage. After rivaroxaban 
discontinuation, the patient 
received prothrombin 
complex concentrate. He 
died 69 days later.
a As defined by the criteria of the International Society of Thrombosis and Haemostasis.[16] 
LMWH: low-molecular-weight heparin; PE: pulmonary embolism; sPESI: simplified Pulmonary Embolism Severity Index.

















































TABLE S2 Serious adverse events (n=68) in the safety population within 3 months of 
enrolment




Progression of oedema (left leg) 49 Yes
Kidney stones 74 Yes
Retrosternal pain 5 Yes




Suspected recurrent pulmonary embolism 7 Yes
Schizoaffective disorder (maniac phase) 64 Yes
Anaemia 55 Yes
Ankle fracture 49 Yes
Infarct pneumonia 2 Yes
Proximal tibial facture 71 Yes
Gastrointestinal bleeding 13 Yes
Chest pain 20 Yes
Exertional dyspnoea 37 Yes
Paradoxical septal motion 91 No
Upper gastrointestinal bleeding 5 Yes
Acute cytomegalovirus (momonucleosis-like) infection 2 Yes
Pleuritis 1 Yes
Reflux oesophagitis 2 Yes
Syncope 12 Yes
Hypermenorrhoea 12 Yes
Urosepsis and pyelonephritis 13 Yes
Allergic reaction (rivaroxaban) 2 Yes
Acute renal failure 53 Yes
Hypermenorrhoea 20 Yes
Pneumonia 2 Yes
Panic attack 57 Yes
Renal colic 1 Yes
Cancer 47 No
Infarction pneumonia 4 Yes
Dyspnoea 4 Yes































































Gastrointestinal bleeding 57 Yes
Angina pectoris 57 Yes
Pancreatic cancer 1 Yes
Bronchial cancer 13 Yes
Suspected pancreatic cancer 2 Yes
Fever 3 Yes
Pneumonia 2 Yes
Chronic obstructive pulmonary disease 33 Yes
Bleeding 57 Yes
Bronchial asthma 35 Yes
Pneumonia 4 Yes
Elevation of troponin 1 Yes
Thoracic pain 32 Yes
Anxious disorder 4 Yes
Suspected deep vein thrombosis 63 No
Prostate cancer 55 No
Chronic inflammatory demyelinating polyneurophathy 4 Yes
Advanced mesothelioma 34 Yes
Bladder-bowel fistula 33 Yes
Lobar pneumonia 70 Yes
Elevation of troponin 1 Yes
Diarrhea 85 Yes
Chest pain 36 Yes
Sepsis 22 Yes
Suspected recurrent pulmonary embolism 75 No
Exacerbation of chronic obsctructive pulmonary disease 7 Yes
Pneumonia 12 Yes
Suspected esophagus cancer 13 Yes
Pneumonia 26 Yes
Pneumonia 34 Yes
Chest pain 5 Yes
Hypotension 29 Yes
Non-ST elevation myocardial infarction 3 Yes
Suspected deep vein thrombosis 2 Yes
Stroke 53 Yes
Chest pain 2 Yes































































Advanced endometrial cancer 26 Yes































































TABLE S3 Answers to Dimension 2 of PEmb-QoL “At what time of day are your lung 
symptoms most intense?”
Week 3 Month 3
When waking up 8.2% 6.1%
At mid-day 8.7% 6.4%
In the evening 16.0% 12.2%
During the night 5.7% 4.0%
At any time of the day 20.0% 14.8%
Never 38.1% 53.9%
Not available 3.3% 2.6%































































TABLE S4 Answers to Dimension 3 of PEmb-QoL “Compared to one year ago, how 
would you rate the condition of your lungs in general now?”
Week 3 Month 3
Much better 4.0% 14.1%
Slightly better 6.4% 8.5%
About the same 19.1% 30.8%
Slightly worse 27.3% 22.6%
Much worse 13.2% 6.8%
No problems 28.2% 15.8%
Not available 1.9% 1.4%































































TABLE S5. Baseline characteristics of the patients who completed the Pulmonary Embolism 
Quality of Life questionnaire at both visits (week 3 and month 3) versus those who did not (at 
either or both visits)
Variable PEmb-QoL assessed at 3 
weeks and 3 months
(N=425)




Age (years), mean (SD; range) 57.0 (16.0; 19-90) 55.2 (18.2; 18-87)
Women, n/N (%) 192/425 (45.2) 74/151 (49.0)
Education Level, n/N (%)
Elementary school 14/384 (3.6) 6/135 (4.4)
Basic primary school 42/384 (10.9) 16/135 (11.9)
Secondary general school 97/384 (25.3) 26/135 (19.3)
Intermediate secondary school 95/384 (24.7) 37/135 (27.4)
A-level 68/384 (17.7) 27/135 (20.0)
University degree 67/384 (17.4) 23/135 (17.0)
Doctorate 1/384 (0.3) 0
Functional Parameters and Biochemical Markers
Body mass index (kg/m²), median 
(Q1-Q3)
27.1 (24.3-30.5) 27.0 (24.4-30.6)
Systolic / diastolic blood pressure 
(mm Hg), mean (SD)
137 (19) / 80 (12) 136 (19) / 80 (12)
Heart rate (beats per minute), mean 
(SD)
78 (13) 77 (13)
Oxygen saturation (%), median 
(Q1-Q3)
97 (96-98) 97 (95-98)































































Respiratory rate (breaths per 
minute), median (Q1-Q3)
16 (15-18) 16 (14-18)
Risk Factors for Pulmonary Embolism and Comorbidities, n/N (%)
Oestrogen use 70/422 (16.6) 22/149 (14.8)
Immobilisation (for at least 3 days) 46/420 (11.0) 12/150 (8.0)
Previous deep vein thrombosis 63/416 (15.1) 24/150 (16.0%)
Previous pulmonary embolism 35/421 (8.3) 9/151 (6.0)
Recent major surgery (past 30 
days)
27/424 (6.4) 11/150 (7.3)
Recent major trauma (past 30 days) 17/425 (4.0) 8/150 (5.3)
Long travel (> 4 hours, past 30 
days)
54/418 (12.9) 16/149 (10.7)
Active cancer 29/420 (6.9) 9/147 (6.1)
Chronic obstructive pulmonary 
disease
21/420 (5.0) 7/149 (4.7)
Chronic heart failure 4/425 (0.9) 3/150 (2.0)
Coronary artery disease 31/422 (7.3) 10/148 (6.8)
Arterial hypertension 172/425 (40.5) 69/149 (46.3)
Diabetes mellitus 26/425 (6.1) 12/151 (7.9)
Simplified Pulmonary Embolism 
Severity Index (sPESI) ≥ 1
94/412 (22.8) 33/144 (22.9)
PEmb-QoL: Pulmonary Embolism Quality of Life questionnaire.































































TABLE S6 Baseline characteristics of the patients who completed the EQ-5D-5L 
questionnaire at both visits (week 3 and month 3) versus those who did not (at either or both 
visits) 
Variable EQ-5D-5L assessed at both 
3 weeks and 3 months
(N=473)




Age (years), mean (SD; range) 56.9 (16.1; 18-90) 55.1 (18.7; 20-86)
Women, n/N (%) 217/473 (45.9) 49/103 (47.6)
Education Level, n/N (%)
Elementary school 15/429 (3.5) 5/90 (5.6)
Basic primary school 46/429 (10.7) 12/90 (13.3)
Secondary general school 102/429 (23.8) 21/90 (23.3)
Intermediate secondary school 113/429 (26.3) 19/90 (21.1)
A-level 78/429 (18.2) 17/90 (18.9)
University degree 74/429 (17.2) 16/90 (17.8)
Doctorate 1/429 (0.2) 0
Functional Parameters and Biochemical Markers
Body mass index (kg/m²), median 
(Q1-Q3)
27.2 (24.4-30.5) 26.5 (24.0-29.5)
Systolic / diastolic blood pressure 
(mm Hg), mean (SD)
136 (19) / 80 (12) 136 (19) / 81 (12)
Heart rate (beats per minute), mean 
(SD)
78 (13) 78 (12)
Oxygen saturation (%), median 
(Q1-Q3)
97 (96-98) 97 (95-98)































































Respiratory rate (breaths per 
minute), median (Q1-Q3)
16 (15-18) 16 (15-18)
Risk Factors for Pulmonary Embolism and Comorbidities, n/N (%)
Oestrogen use 76/470 (16.2) 16/101 (15.8)
Immobilisation (for at least 3 days) 49/467 (10.5) 9/103 (8.7)
Previous deep vein thrombosis 69/464 (14.9) 18/102 (17.6)
Previous pulmonary embolism 36/469 (7.7) 8/103 (7.8)
Recent major surgery (past 30 
days)
31/471 (6.6) 7/103 (6.8)
Recent major trauma (past 30 days) 21/472 (4.4) 4/103 (3.9)
Long travel (> 4 hours, past 30 
days)
59/464 (12.7) 11/103 (10.7)
Active cancer 29/467 (6.2) 9/100 (9.0)
Chronic obstructive pulmonary 
disease
22/469 (4.7) 6/100 (6.0)
Chronic heart failure 4/473 (0.8) 3/102 (2.9)
Coronary artery disease 30/469 (6.4) 11/101 (10.9)
Arterial hypertension 194/471 (41.2) 47/103 (45.6)
Diabetes mellitus 33/473 (7.0) 5/103 (4.9)
Simplified Pulmonary Embolism 
Severity Index (sPESI) ≥ 1
97/457 (21.2) 30/99 (30.3)































































































































Formulas for the Calculation of the Pulmonary Embolism Quality of Life (PEmb-QoL) 
questionnaire
Frequency of complaints (Dimension 1) 
The transformation from n_points} to the ratio 100−% was done using the following formula:




⋅ 𝑛𝑚𝑖𝑠𝑠= 100― 𝑛𝑝𝑜𝑖𝑛𝑡𝑠― 8 + 𝑛𝑚𝑖𝑠𝑠 ⋅ 𝑚𝑖𝑛𝑝𝑜𝑖𝑛𝑡
0.32― 0.04 ⋅ 𝑛𝑚𝑖𝑠𝑠
Limitation daily life (Dimension 4) 
The transformation from n_{points} to the ratio 100−% was done using the following formula (if the 
first question was = 0 or missing):




⋅ 𝑛𝑚𝑖𝑠𝑠= 100― 𝑛𝑝𝑜𝑖𝑛𝑡𝑠― 12 + 𝑛𝑚𝑖𝑠𝑠 ⋅ 𝑚𝑖𝑛𝑝𝑜𝑖𝑛𝑡
0.24― 0.02 ⋅ 𝑛𝑚𝑖𝑠𝑠
The transformation from n_points to the ratio 100−% was done using the following formula (if the 
first question was > 0):




⋅ 𝑛𝑚𝑖𝑠𝑠= 100― 𝑛𝑝𝑜𝑖𝑛𝑡𝑠― 13 + 𝑛𝑚𝑖𝑠𝑠0.26― 0.02 ⋅ 𝑛𝑚𝑖𝑠𝑠
Work-related problems (Dimension 5) 




⋅ 𝑛𝑚𝑖𝑠𝑠= 100― 𝑛𝑝𝑜𝑖𝑛𝑡𝑠― 4 + 𝑛𝑚𝑖𝑠𝑠 ⋅ 𝑚𝑖𝑛𝑝𝑜𝑖𝑛𝑡
0.04― 1 ⋅ 𝑛𝑚𝑖𝑠𝑠
Social limitations (Dimension 6) 
1=0% → 5=100%































































Intensity of complaints (Dimensions 7-8) 
The transformation from n_points to the ratio % was done using the following formula:
%=




⋅ 𝑛𝑚𝑖𝑠𝑠= 𝑛𝑝𝑜𝑖𝑛𝑡𝑠― 2 + 𝑛𝑚𝑖𝑠𝑠 ⋅ 𝑚𝑖𝑛𝑝𝑜𝑖𝑛𝑡0.100― 0.05 ⋅ 𝑛𝑚𝑖𝑠𝑠
Emotional complaints (Dimension 9) 
The transformation from n_points to the ratio 100−% was done using the following formula:




⋅ 𝑛𝑚𝑖𝑠𝑠= 100― 𝑛𝑝𝑜𝑖𝑛𝑡𝑠― 10 + 𝑛𝑚𝑖𝑠𝑠 ⋅ 𝑚𝑖𝑛𝑝𝑜𝑖𝑛𝑡
0.5― 0.05 ⋅ 𝑛𝑚𝑖𝑠𝑠
with the following notation:
 : sum of points over all items per patient𝑛𝑝𝑜𝑖𝑛𝑡𝑠
 : number of missing items𝑛𝑚𝑖𝑠𝑠
 : maximal possible sum over all items𝑚𝑎𝑥𝑛𝑝𝑜𝑖𝑛𝑡𝑠
 : minimal possible sum over all items𝑚𝑖𝑛𝑛𝑝𝑜𝑖𝑛𝑡𝑠
 : maximal possible value per item𝑚𝑎𝑥𝑝𝑜𝑖𝑛𝑡
 : minimal possible value per item𝑚𝑖𝑛𝑝𝑜𝑖𝑛𝑡
Total
For the present analysis, the specific dimensions are are weighted based on their number of items. The 
number of items per dimension is distibuted as follows:
- frequency of complaints (foc): 8
- limitations of activity in daily life (adl): 12 or 13 (depending on the value of ‘I do not work’)
- work-related problems (wrp): 4
- social limitation (sl): 1
- intensity of problems (iop): 2
- emotional complaints (ep): 10
resulting in a total of 37 or 38 items over all six dimensions. For calculation a total of 37.5 items is 
used as the number of 12 or 13 items in the adl-dimension is almost 50:50. The total score is then 
calculated as follows:
%




















































































Multiple imputation (MCMC, assuming all dimensions have a joint multivariate normal distribution) 
was performed if a dimension was completely missing. The number of missing dimensions was 3.6%. 
Back to top






























































The figure illustrates the evolution in disease-specific quality of life for each of the PEmb-QoL dimensions 
and for the whole PEmb-QoL score between Week 3 (blue line) and Month 3 (orange line). The six 
dimensions contributing to scores are summed, weighted, and transformed to a percentage scale (0 to 100), 
with higher scores (larger area of the polygon) indicating worse quality of life and lower scores (smaller area 
of the polygon) indicating better quality of life. 





























































Self−care problems Usual activity problems Overall
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